Compare ARTNA & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARTNA | NGNE |
|---|---|---|
| Founded | 1905 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Supply | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 344.1M | 327.8M |
| IPO Year | N/A | 2014 |
| Metric | ARTNA | NGNE |
|---|---|---|
| Price | $32.22 | $22.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $60.13 |
| AVG Volume (30 Days) | 24.2K | ★ 157.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $925,000.00 |
| Revenue This Year | $7.82 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | $15.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $30.50 | $6.88 |
| 52 Week High | $36.19 | $37.27 |
| Indicator | ARTNA | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 38.42 | 60.32 |
| Support Level | $31.71 | $19.44 |
| Resistance Level | $33.00 | $25.79 |
| Average True Range (ATR) | 0.88 | 2.29 |
| MACD | -0.20 | 0.35 |
| Stochastic Oscillator | 20.24 | 63.16 |
Artesian Resources Corp operates as a holding company with a focus on water distribution and wastewater services. Its regulated utility segment includes subsidiaries providing water and wastewater services in Delaware, Maryland, and Pennsylvania. Water distribution spans residential, commercial, industrial, and municipal sectors, while wastewater services are offered in Sussex County, Delaware. The company also engages in non-utility businesses, offering service line protection plans, engineering services, and contract operations for water and wastewater systems. The regulated utility segment constitutes the portion of the company's operations, subject to regulations by Delaware, Maryland, and Pennsylvania.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.